

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
October 18, 2021**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

Emergent BioSolutions Inc.

File No. 1-33137 - CF#36582

Emergent BioSolutions Inc. submitted an application under Rule 24b-2 requesting an extension of a previous grant of confidential treatment for information it excluded from an exhibit to a Form 10-Q filed on August 3, 2018.

Based on representations by Emergent BioSolutions Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit will not be released to the public for the time period specified:

Exhibit 10.2	through September 30, 2026
Exhibit 10.3	through September 30, 2026
Exhibit 10.4	through September 30, 2026
Exhibit 10.5	through September 30, 2026

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Robert Errett
Chief, Disclosure Management Office